In this workshop, CIRS brought together senior representatives from regulators, HTA agencies, pharmaceutical companies, payers, academics and patient organisations to discuss the impact of regulatory and HTA collaborative models and how these should evolve.
This two-day workshop consisted of a series of sessions featuring presentations and panel discussions, as well as three parallel breakout discussions. The objectives were to:
- Assess the impact of different regulatory and HTA collaborative models on development, regulatory review and HTA assessment.
- Understand the experiences and learnings from current regulatory-regulatory, HTA-HTA and regulatory-HTA collaborative models – what can be leant at national, regional and international levels? How does these models influence companies’ development strategy and jurisdictional roll out?
- Make recommendations on the current and future development of regulatory and HTA collaboration, such as the EU HTA Regulation and its jurisdictional implementation, international initiatives outside of Europe and cross-continental partnerships.
This workshop synopsis summarises key messages and recommendations from the presentations and breakout discussions.
